-
Posted by
Two Blokes Jul 26 -
Filed in
Stock
-
3 views
McKesson delivered strong double-digit growth in revenue, earnings, and free cash flow in fiscal 2025, outperforming the S&P 500 significantly. The planned spin-off of the underperforming Medical-Surgical Solutions segment will sharpen McKesson's focus on higher-growth, higher-margin oncology and biopharma businesses. Management and analysts expect continued double-digit earnings growth, supported by robust share buybacks and optimistic long-term guidance.
